CRAD as a cytoskeletal tumour suppressor

George Eng^{1

2}, Jonathan Braverman¹, Ömer H Yilmaz^{3

4}

Affiliations

¹ The David H. Koch Institute for Integrative Cancer Research at MIT, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
² Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
³ The David H. Koch Institute for Integrative Cancer Research at MIT, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. ohyilmaz@mit.edu.
⁴ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. ohyilmaz@mit.edu.

Comment

George Eng et al. Nat Cell Biol. 2018 Nov.

. 2018 Nov;20(11):1232-1233.

doi: 10.1038/s41556-018-0225-x.

George Eng^{1

2}, Jonathan Braverman¹, Ömer H Yilmaz^{3

4}

¹ The David H. Koch Institute for Integrative Cancer Research at MIT, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
² Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
³ The David H. Koch Institute for Integrative Cancer Research at MIT, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. ohyilmaz@mit.edu.
⁴ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. ohyilmaz@mit.edu.

No abstract available

Comment on

Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via β-catenin.
Jung YS, Wang W, Jun S, Zhang J, Srivastava M, Kim MJ, Lien EM, Shang J, Chen J, McCrea PD, Zhang S, Park JI. Jung YS, et al. Nat Cell Biol. 2018 Nov;20(11):1303-1314. doi: 10.1038/s41556-018-0215-z. Epub 2018 Oct 22. Nat Cell Biol. 2018. PMID: 30361697 Free PMC article.